[{"address1": "12730 High Bluff Drive", "address2": "Suite 400", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 500 8800", "website": "https://kuraoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.", "fullTimeEmployees": 192, "companyOfficers": [{"maxAge": 1, "name": "Dr. Troy Edward Wilson J.D., Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 1296258, "exercisedValue": 1234936, "unexercisedValue": 15624}, {"maxAge": 1, "name": "Ms. Kathleen  Ford", "age": 77, "title": "Chief Operating Officer", "yearBorn": 1947, "fiscalYear": 2024, "totalPay": 868935, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Teresa Brophy Bair Esq., J.D.", "age": 53, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 745021, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  Doyle", "age": 53, "title": "Senior Vice President of Finance & Accounting", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Francis J. Burrows Ph.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roger  Bakale Ph.D.", "title": "Senior Vice President of Manufacturing & Supply Chain", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maureen  Clancy M.B.A.", "title": "VP and Global Head of Program Leadership & Project Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mollie  Leoni M.D.", "age": 46, "title": "Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian T. Powl M.B.A., M.S.", "age": 50, "title": "Chief Commercial Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Samir  Vattompadam M.S.", "title": "Senior Vice President of Global Program Leadership", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.24, "open": 6.11, "dayLow": 5.6, "dayHigh": 6.14, "regularMarketPreviousClose": 6.24, "regularMarketOpen": 6.11, "regularMarketDayLow": 5.6, "regularMarketDayHigh": 6.14, "payoutRatio": 0.0, "beta": 0.496, "forwardPE": -2.1123595, "volume": 2675771, "regularMarketVolume": 2675771, "averageVolume": 1313396, "averageVolume10days": 1239820, "averageDailyVolume10Day": 1239820, "bid": 5.55, "ask": 5.81, "bidSize": 1, "askSize": 10, "marketCap": 488281312, "fiftyTwoWeekLow": 5.41, "fiftyTwoWeekHigh": 23.48, "priceToSalesTrailing12Months": 7.181558, "fiftyDayAverage": 6.3829, "twoHundredDayAverage": 11.878075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -150555760, "profitMargins": -2.67516, "floatShares": 64118079, "sharesOutstanding": 86574704, "sharesShort": 8283602, "sharesShortPriorMonth": 8802791, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.095699996, "heldPercentInsiders": 0.01092, "heldPercentInstitutions": 0.94323, "shortRatio": 5.56, "shortPercentOfFloat": 0.0959, "impliedSharesOutstanding": 86574704, "bookValue": 4.511, "priceToBook": 1.250277, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -181887008, "trailingEps": -2.09, "forwardEps": -2.67, "enterpriseToRevenue": -2.214, "enterpriseToEbitda": 0.743, "52WeekChange": -0.73755234, "SandP52WeekChange": 0.09362543, "quoteType": "EQUITY", "currentPrice": 5.64, "targetHighPrice": 40.0, "targetLowPrice": 8.0, "targetMeanPrice": 25.91667, "targetMedianPrice": 28.0, "recommendationMean": 1.46667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 658190976, "totalCashPerShare": 7.603, "ebitda": -202588000, "totalDebt": 19354000, "quickRatio": 7.934, "currentRatio": 8.068, "totalRevenue": 67991000, "debtToEquity": 5.311, "revenuePerShare": 0.781, "returnOnAssets": -0.19597, "returnOnEquity": -0.41838002, "grossProfits": -107061000, "freeCashflow": -95008752, "operatingCashflow": 111234000, "grossMargins": -1.57463, "ebitdaMargins": -2.9796302, "operatingMargins": -4.58605, "financialCurrency": "USD", "symbol": "KURA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1748043003, "regularMarketTime": 1748030401, "shortName": "Kura Oncology, Inc.", "longName": "Kura Oncology, Inc.", "fiftyTwoWeekLowChange": 0.23000002, "fiftyTwoWeekLowChangePercent": 0.04251387, "fiftyTwoWeekRange": "5.41 - 23.48", "fiftyTwoWeekHighChange": -17.84, "fiftyTwoWeekHighChangePercent": -0.7597956, "fiftyTwoWeekChangePercent": -73.75523, "earningsTimestamp": 1746129901, "earningsTimestampStart": 1754477940, "earningsTimestampEnd": 1754913600, "earningsCallTimestampStart": 1746131400, "earningsCallTimestampEnd": 1746131400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.09, "epsForward": -2.67, "epsCurrentYear": -2.05999, "priceEpsCurrentYear": -2.7378774, "exchange": "NMS", "market": "us_market", "fiftyDayAverageChange": -0.7429004, "fiftyDayAverageChangePercent": -0.116389155, "twoHundredDayAverageChange": -6.238075, "twoHundredDayAverageChangePercent": -0.5251756, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1442410200000, "postMarketChangePercent": 1.76419, "postMarketPrice": 5.7395, "postMarketChange": 0.0995002, "regularMarketChange": -0.5999999, "regularMarketDayRange": "5.6 - 6.14", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1313396, "messageBoardId": "finmb_282774456", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "regularMarketChangePercent": -9.615383, "regularMarketPrice": 5.64, "displayName": "Kura Oncology", "trailingPegRatio": null, "__fetch_time": "2025-05-24"}]